Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 21, 2012 - Issue 6
Submit an article Journal homepage
478
Views
24
CrossRef citations to date
0
Altmetric
Drug Evaluations

Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia

Xavier ThomasHospices Civils de Lyon, Lyon-Sud Hospital, Hematology Department, Pavillon Marcel Bérard, Bat.1G, 69495 Pierre-Bénite, France+33 478862235; +33 472678880; [email protected].
, MD PhD
Pages 871-878 | Published online: 16 Apr 2012

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Mehrdad Hefazi & Mark R Litzow. (2018) Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood and Lymphatic Cancer: Targets and Therapy 8, pages 47-61.
Read now
Xavier Thomas & Caroline Le Jeune. (2016) Treating adults with acute lymphocytic leukemia: new pharmacotherapy options. Expert Opinion on Pharmacotherapy 17:17, pages 2319-2330.
Read now
Michael S. Mathisen, Hagop Kantarjian, Deborah Thomas, Susan O’Brien & Elias Jabbour. (2013) Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leukemia & Lymphoma 54:12, pages 2592-2600.
Read now
David M Goldenberg & Robert M Sharkey. (2012) Using antibodies to target cancer therapeutics. Expert Opinion on Biological Therapy 12:9, pages 1173-1190.
Read now

Articles from other publishers (20)

Si‐Man Huang, Chao‐Ling Wan, Han‐Yu Cao, Yan‐Yan Li, Chong‐Sheng Qian, Hai‐Xia Zhou, Ming‐Zhu Xu, Xiao‐Hui Hu, Lan Dai, Hai‐Ping Dai & Sheng‐Li Xue. (2023) Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy . Clinical Case Reports 11:12.
Crossref
Nadya Jammal, Serena Chew, Elias Jabbour & Hagop Kantarjian. (2020) Antibody based therapy in relapsed acute lymphoblastic leukemia. Best Practice & Research Clinical Haematology 33:4, pages 101225.
Crossref
Katharine A. Hodby & David I. Marks. (2020) Recent Advances in the Management of Acute Lymphoblastic Leukaemia. Current Treatment Options in Oncology 21:3.
Crossref
Sneha Tandon & Angela S. Punnett. 2019. Advances in Hematologic Malignancies. Advances in Hematologic Malignancies.
Rajendar K. Mittapalli, Sven Stodtmann, Anna Friedel, Rajeev M. Menon, Earle Bain, Sven Mensing & Hao Xiong. (2019) An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR. The Journal of Clinical Pharmacology.
Crossref
Elias Jabbour, Anjali S. Advani, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Nicola Gökbuget, Giovanni Martinelli, Susan O'Brien, Jane Liang White, Tao Wang, M. Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Daniel J. DeAngelo & Hagop M. Kantarjian. (2019) Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology 94:4, pages 408-416.
Crossref
Jun Ma, Ting Liu, Jie Jin, Jianda Hu, Qifa Liu, Jianxiang Wang, Zhixiang Shen, Xin Du, Bin Jiang & Xianhua Meng. (2018) An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia. International Journal of Hematologic Oncology 7:2, pages IJH06.
Crossref
Hagop KantarjianElias Jabbour. (2018) Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. American Society of Clinical Oncology Educational Book:38, pages 574-578.
Crossref
Sabina Chiaretti, Elias Jabbour & Dieter Hoelzer. (2018) “Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions”—Treatment of ALL. Clinical Lymphoma Myeloma and Leukemia 18:5, pages 301-310.
Crossref
Elias J. Jabbour, Daniel J. DeAngelo, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Nicola Gökbuget, Susan O'Brien, Tao Wang, M. Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Anjali S. Advani & Hagop M. Kantarjian. (2018) Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer 124:8, pages 1722-1732.
Crossref
Hagop Kantarjian, Farhad Ravandi, Nicholas J Short, Xuelin Huang, Nitin Jain, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Joseph D Khoury, Jeffrey Jorgensen, Yesid Alvarado, Marina Konopleva, Guillermo Garcia-Manero, Tapan Kadia, Musa Yilmaz, Gautam Bortakhur, Jan Burger, Steven Kornblau, William Wierda, Courtney DiNardo, Alessandra Ferrajoli, Jovitta Jacob, Rebecca Garris, Susan O'Brien & Elias Jabbour. (2018) Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. The Lancet Oncology 19:2, pages 240-248.
Crossref
Daniel Merk & Manfred Schubert-Zsilavecz. 2017. Drug Selectivity. Drug Selectivity 207 245 .
Elias Jabbour & Hagop Kantarjian. (2016) Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Advances 1:3, pages 260-264.
Crossref
Binsah George, Hagop Kantarjian, Elias Jabbour & Nitin Jain. (2016) Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy 8:2, pages 135-143.
Crossref
Elias Jabbour, Susan O'Brien, Marina Konopleva & Hagop Kantarjian. (2015) New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121:15, pages 2517-2528.
Crossref
Elias Jabbour, Susan O’Brien, Farhad Ravandi & Hagop Kantarjian. (2015) Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125:26, pages 4010-4016.
Crossref
Monika Podhorecka, Justyna Markowicz, Agnieszka Szymczyk & Johannes Pawlowski. (2014) Target Therapy in Hematological Malignances: New Monoclonal Antibodies. International Scholarly Research Notices 2014, pages 1-16.
Crossref
Hans-Peter Gerber, Frank E. Koehn & Robert T. Abraham. (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Natural Product Reports 30:5, pages 625.
Crossref
Ingrid Sassoon & Véronique Blanc. 2013. Antibody-Drug Conjugates. Antibody-Drug Conjugates 1 27 .
Frank E. Koehn. 2013. Natural Products and Cancer Drug Discovery. Natural Products and Cancer Drug Discovery 97 119 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.